Hyperlipidemia, COVID-19 and acute pancreatitis: A tale of three entities

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the ongoing pandemic of coronavirus disease 2019 (COVID-19), which presented as not only respiratory symptoms, but various digestive manifestations including pancreatic injury and acute pancreatitis (AP). The underlying mechanism is...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of the medical sciences 2022-09, Vol.364 (3), p.257-263
Main Authors: Tang, Qiuyi, Gao, Lin, Tong, Zhihui, Li, Weiqin
Format: Article
Language:English
Subjects:
Acute Disease
Acute pancreatitis
COVID-19
COVID-19 - complications
Humans
Hyperlipidemia
Hyperlipidemias - complications
Hyperlipidemias - epidemiology
Pancreatic injury
Pancreatitis - etiology
Review
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the ongoing pandemic of coronavirus disease 2019 (COVID-19), which presented as not only respiratory symptoms, but various digestive manifestations including pancreatic injury and acute pancreatitis (AP). The underlying mechanism is still unclear. Hypertriglyceridemia has become one of the leading causes of AP in recent years and hyperlipidemia is highly reported in COVID-19 cases. The current narrative review aimed to explore the associations between AP, COVID-19 and hyperlipidemia. Substantial cases of COVID-19 patients complicated with AP were reported, while the incidence of AP in the COVID-19 population was relatively low. Hyperlipidemia was common in COVID-19 patients with a pooled incidence of 32.98%. Hyperlipidemia could be a mediating factor in the pathogenesis of AP in COVID-19 patients. Further studies are warranted to clarify the relationship among AP, lipid metabolism disorders and COVID-19.
ISSN:0002-9629
1538-2990
DOI:10.1016/j.amjms.2022.03.007